Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.59 |
| ▸ | NOTUM | Q6P988 | 9/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10447781 | 0.83 | NOTUM (0.78) | NOTUMCYP19A1KEAP1 | |
| SCHEMBL6870744 | 0.82 | NOTUM (0.51) | KCNJ1NOTUMALDH1A1KDM4EMAPK1 | |
| SCHEMBL6870749 | 0.82 | NOTUM (0.51) | KCNJ1NOTUMALDH1A1KDM4EMAPK1 | |
| SCHEMBL17981459 | 0.81 | NOTUM (0.43) | KCNJ1NOTUMALDH1A1KDM4EMAPK1 | |
| SCHEMBL4536618 | 0.79 | NOTUM (0.63) | KCNJ1NOTUMALDH1A1KDM4EMAPK1 | |
| SCHEMBL6850789 | 0.78 | NOTUM (0.55) | KCNJ1NOTUMALDH1A1KDM4EMAPK1 | |
| SCHEMBL23501721 | 0.75 | KCNJ1 (0.62) | KCNJ1NOTUMALDH1A1KDM4EMAPK1 | |
| SCHEMBL1663879 | 0.74 | KCNJ1 (1.00) | KCNJ1NOTUMALDH1A1KDM4EMAPK1 | |
| SCHEMBL8491479 | 0.74 | NOTUM (0.46) | KCNJ1NOTUMALDH1A1KDM4EMAPK1 | |
| SCHEMBL8491470 | 0.74 | NOTUM (0.46) | KCNJ1NOTUMALDH1A1KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109666158-B | Hybrid dynamic polymer and application thereof | 厦门逍扬运动科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3974426-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | Indiana University Research and Technology Corporation (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| US-10766890-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-3116316-B1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | UNIV INDIANA RES & TECH CORP (US) | 2019-07-10 | — | — | EP | disclosed |
| WO-2002064552-A1 | 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002046204-A1 | 6-0-CARBAMOYL KETOLIDE DERIVATIVES OF ERYTHROMYCIN USEFUL AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| US-5977075-A | N-aroylamino acid amides as endothelin inhibitors | NOVARTIS AG (CH) | 1999-11-02 | — | — | US | disclosed |
| EP-0821670-A1 | N-AROYLAMINO ACID AMIDES AS ENDOTHELIN INHIBITORS | Novartis AG (CH) | 1998-02-04 | — | — | EP | disclosed |
| US-5703106-A | TREATING VARIOUS CARDIOVASCULAR, UROGENITAL, BRAIN DISORDERS | JAPAT LTD. (CH) | 1997-12-30 | — | — | US | disclosed |
| CN-1145075-A | Antagonist's of endothelin receptors | JAPAT LTD (CH) | 1997-03-12 | — | — | CN | disclosed |
| EP-0753004-A1 | ANTAGONISTS OF ENDOTHELIN RECEPTORS | Japat Ltd (CH) | 1997-01-15 | — | — | EP | disclosed |
| WO-1996033170-A1 | N-AROYLAMINO ACID AMIDES AS ENDOTHELIN INHIBITORS | NOVARITS AG (CH) | 1996-10-24 | — | — | WO | disclosed |
| WO-1996010559-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
| WO-1995026360-A1 | ANTAGONISTS OF ENDOTHELIN RECEPTORS | JAPAT LTD. (CH) | 1995-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | HAVCR2, MAVS, FABP1 | KCNJ1 4772/4885NOTUM 2430/4885ALDH1A1 4382/4885 |
| US-10766890-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | KCNJ1 4869/4885NOTUM 2257/4885ALDH1A1 4316/4885 |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | HAVCR2, MAVS, FABP1 | KCNJ1 4772/4885NOTUM 2430/4885ALDH1A1 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.